Αποτελέσματα Αναζήτησης
20 Ιουν 2022 · Secondary causes of sclerosing cholangitis should be excluded. Importantly, 50-80% of people with PSC also have IBD. Therefore, elevation in serum liver tests, especially serum alkaline phosphatase (ALP), should raise suspicion for PSC and trigger further evaluation ( Fig. 1 ).
It can be treated with minor interventions such as continued antibiotic use and monitoring, or in more serious cases, laparoscopic surgery intervention, and possibly a liver transplant.
1 ημέρα πριν · Apart from previous reports on secondary sclerosing cholangitis (SSC) from different kinds of drugs, this has recently been demonstrated in patients on treatment with checkpoint inhibitors (CPIs). SSC was reported in the 1980s after local treatment of liver metastases from colon cancer with hepatic intraarterial infusion of floxuridine, a ...
Sclerosing cholangitis is considered primary (PSC) if no underlying etiology is identified or secondary (SSC) if related to another identifiable cause. In this article, we will review the clinical features, pathogenesis, diagnosis, and imaging findings of PSC and SSC, with an emphasis on features that may aid in the distinction of these entities.
Secondary sclerosing cholangitis is an entity with morphologic, radiologic, and clinical features that is similar to PSC but in which the underlying cause of ductal inflammation and sclerosis is known.
We recommend that cholestatic liver biochemistry with typical cholangiographic features in the absence of other identifiable causes of secondary sclerosing cholangitis is usually sufficient for a diagnosis of PSC (strength of recommendation: STRONG; quality of evidence: MODERATE).
11 Δεκ 2015 · Secondary sclerosing cholangitis in critically ill patients (SSC-CIP) is an important differential diagnosis in patients presenting with cholestasis and PSC-like cholangiographic changes in endoscopic retrograde cholangiography (ERC).
